Drug intelligence / Profile preview

KVD-998083

Development stage: Preclinical
Lead developer: KalVista Pharmaceuticals
Modality: Small Molecules
Administration: Oral

Overview

KVD-998083 is a small molecule drug developed by KalVista Pharmaceuticals. It is a selective inhibitor of coagulation Factor XIIa, designed to prevent vascular leakage and the cleavage of high molecular weight kininogen, which are key processes in the pathogenesis of hereditary angioedema (HAE). The drug has demonstrated protective effects against captopril-induced vascular leakage in preclinical mouse models. Its primary indication under investigation is hereditary angioedema, a rare genetic disorder characterized by recurrent episodes of severe swelling[1][2].

Targets

FXIIa (Coagulation Factor XIIa)

Beyond the preview

Go deeper on KVD-998083.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KVD-998083.

Explore the full profile